RPG Life Sciences (RPGLIFE) Fundamentals 2026 — P/E 43.1x, Revenue Analysis | SniperIQ
RPG Life Sciences (RPGLIFE) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹5,023 Crore, trading at ₹3005.50 on the BSE. This SniperIQ fundamentals page covers RPG Life Sciences's valuation (P/E 43.1x, P/B 8.2x), profitability (net margin 16.3%), revenue (₹708 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is RPG Life Sciences's market cap?
RPG Life Sciences (RPGLIFE) has a market capitalization of approximately ₹5,023 Crore, trading at ₹3005.50 on the BSE. Market cap moves with the live share price.
What is RPG Life Sciences's P/E ratio?
RPG Life Sciences's trailing twelve-month P/E ratio is 43.1x, with a price-to-book (P/B) of 8.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is RPG Life Sciences?
RPG Life Sciences runs a net profit margin of 16.3%, a gross margin of 46.8%, and an operating margin of 17.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does RPG Life Sciences generate?
RPG Life Sciences reported revenue of ₹708 Crore for fiscal year 2026, with net income of ₹115 Crore and earnings per share (EPS) of 69.64. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does RPG Life Sciences pay a dividend?
RPG Life Sciences offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is RPG Life Sciences financially healthy?
RPG Life Sciences carries a debt-to-equity ratio of 0.03x and a current ratio of 3.48x, with a market beta of -0.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is RPG Life Sciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For RPG Life Sciences (RPGLIFE) the key facts are: market cap ₹5,023 Crore, P/E 43.1x, revenue ₹708 Crore, 52-week range 1731.25-3080.9. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track RPG Life Sciences's full fundamentals live
Get RPG Life Sciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.